North East and North Cumbria
ICS Formulary
 
back
6 Endocrine system
06-06-02 Denosumab

Denosumab Xgeva®
Formulary
  • Denosumab 70mg in 1ml (120mg) vial is approved for the prevention of skeletal-related events in adults with bone metastases from solid tumours in line with NICE 
    • Note: denosumab is not approved for therapy induced bone loss in non- metastatic prostate cancer (NICE).


  • North Cumbria only
    • New patients        Red
    • Exisiting patients  Green plus
Link  MHRA Drug Safety Updates: Denosumab
Link  NICE TA265: Bone metastases from solid tumours - denosumab: guidance

Red View adult BNF  View SPC online  View childrens BNF
Denosumab Prolia®
Formulary
  • Denosumab 60mg in 1ml solution in prefilled syringe is approved for use in the treatment of postmenopausal osteoporosis in line with NICE. Also approved for male patients who dont tolerate bisphosphonates or strontium ranelate. 
  • NOTE: Denosumab will remain as Green plus in most localities until a shared care guideline has been produced. 
Link  NICE TA204: Osteoporotic fractures - denosumab
Link  MHRA Drug Safety Updates: Denosumab
Link  North of Tyne, Gateshead and North Cumbria: DENOSUMAB (Prolia®) 60mg sc twice yearly for osteoporosis Information for Treatment of Adults in Primary Care
Link  CD&TV APC Information sheet to support prescribing and monitoring of Denosumab (Prolia®

Amber View adult BNF  View SPC online  View childrens BNF